HLA Class I Expression and Its Alteration by Preoperative Hyperthermo-Chemoradiotherapy in Patients with Rectal Cancer

Objective Enhancing immunologic responses, including human leukocyte antigen (HLA) class I expression on tumor cells and recognition and elimination of tumor cells by tumor-specific cytotoxic T lymphocyte (CTL), is considered a novel concept of radiotherapy. The present study examined patients who underwent preoperative hyperthermo-chemoradiotherapy (HCRT) for locally advanced rectal cancer to assess the correlation between HLA class I expression and clinical outcome. Materials and Methods Seventy-eight patients with locally advanced rectal adenocarcinoma who received preoperative HCRT were enrolled. The median age of the patients was 64 years (range, 33–85 years) and 4, 18, and 56 patients had clinical stage I, II and III disease, respectively. Formalin-fixed and paraffin-embedded tissues excised before and after HCRT were subjected to immunohistochemical analysis with an anti-HLA class I-A, B, C antibody. HLA class I expression was graded according to tumor cell positivity. Results In pre-HCRT, the number of specimens categorized as Grade 0 and 1 were 19 (24%) and 58 (74%), respectively. Only 1 patient (1%) showed Grade 2 expression. However, 6 (8%), 27 (35%), 7 (9%), and 12 (15%) post-HCRT specimens were graded as Grade 0, 1, 2, and 3, respectively. There was a significant increase in HLA class I expression in post-HCRT specimens (p<0.01). However, neither pre- nor post-HCRT HLA class I expression affected overall survival and distant metastasis-free survival in clinical stage III patients. Univariate analysis revealed that Post-HCRT HLA class I expression showed a significant negative relationship with LC (p<0.05). Nevertheless, multivariate analysis showed that there was no correlation between HLA class I expression and clinical outcome. Conclusion HCRT increased HLA class I expression in rectal cancer patients. However, multivariate analysis failed to show any correlation between the level of HLA class I expression and prognosis.

[1]  David L. Woods,et al.  Combination Therapy with Local Radiofrequency Ablation and Systemic Vaccine Enhances Antitumor Immunity and Mediates Local and Distal Tumor Regression , 2013, PloS one.

[2]  H. Fujii,et al.  Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. , 2012, Cancer research.

[3]  T. Nakano,et al.  Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy. , 2011, Anticancer research.

[4]  Yoshiyuki Suzuki,et al.  Expression of hypoxia-inducible factor 1α predicts clinical outcome after preoperative hyperthermo-chemoradiotherapy for locally advanced rectal cancer. , 2011, Journal of radiation research.

[5]  M. Takahara,et al.  HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. , 2010, Oncology reports.

[6]  H. Shirato,et al.  Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. , 2010, Cancer research.

[7]  N. Sato,et al.  Human leukocyte antigen class I down‐regulation in muscle‐invasive bladder cancer: Its association with clinical characteristics and survival after cystectomy , 2009, Cancer science.

[8]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[9]  H. Fujii,et al.  Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma , 2008, British Journal of Cancer.

[10]  H. Putter,et al.  Clinical impact of HLA class I expression in rectal cancer , 2007, Cancer Immunology, Immunotherapy.

[11]  M. Nishimura,et al.  HLA class I antigen expression is associated with a favorable prognosis in early stage non‐small cell lung cancer , 2007, Cancer science.

[12]  T. Yamashita,et al.  Prognostic significance of HLA class I expression in osteosarcoma defined by anti‐pan HLA class I monoclonal antibody, EMR8‐5 , 2006, Cancer science.

[13]  S. Ferrone,et al.  HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. , 2006, Cancer research.

[14]  N. Kawashima,et al.  The Combination of Ionizing Radiation and Peripheral Vaccination Produces Long-term Survival of Mice Bearing Established Invasive GL261 Gliomas , 2006, Clinical Cancer Research.

[15]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[16]  J. Schlom,et al.  Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes , 2004, Cancer Research.

[17]  S. Okabe,et al.  Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs , 2003, Journal of Cancer Research and Clinical Oncology.

[18]  S. Ferrone,et al.  HLA class I antigen defects in maxillary sinus squamous cell carcinoma: potential prognostic significance☆ , 2003 .

[19]  S. Ferrone,et al.  Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[21]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[22]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[23]  H. Seigler,et al.  Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. , 1996, Cellular immunology.

[24]  I. Ellis,et al.  Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis , 2006, International journal of cancer.